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Abstract. In vertebrates, different isoforms of fibrob-
last growth factor 2 (FGF2) exist, which differ by their
N-terminal extension. They show different localization
and expression levels and exert distinct biological ef-
fects. Nevertheless, genetic inactivation of all FGF2 iso-
forms in the mouse results in only mild phenotypes.
Here, we analyzed mouse FGF2, and show that, as in the
human, mouse FGF2 contains CTG-initiated high mole-
cular-weight (HMW) isoforms, which contain a nuclear
localization signal, and which mediate localization of
this isoform to the nucleus. Using green fluorescent pro-
tein-FGF2 fusions, we furthermore observed, that C-ter-
CMLS, Cell. Mol. Life Sci. 60 (2003) 2254–2265
1420-682X/03/102254-12
DOI 10.1007/s00018-003-3258-6
© Birkhäuser Verlag, Basel, 2003
CMLS Cellular and Molecular Life Sciences
minal deletions disable nuclear localization of the short
low-molecular-weight (LMW) 18-kDa isoform. This
loss of specific localization is accompanied by a loss in
heparin binding. We therefore suggest that, first, local-
ization of mouse FGF2 is comparable to that in other ver-
tebrates and, second, FGF2 contains at least two se-
quences important for nuclear localization, a nuclear lo-
calization sequence at the N terminus which is only
contained in the HMW isoform, and another sequence at
the C terminus, which is only required for localization of
the LMW 18-kDa isoform. 
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Basic fibroblast growth factor (FGF2; heparin-binding
growth factor 2) is the prototype of the FGF family, and
was first isolated from bovine pituitary gland and from
brain. Since then, identification of FGF family members
has continued and, currently, at least 23 distinct members
have been identified in mammals. Members of the FGF
family demonstrate a variety of properties, depending on
cell type and context. FGFs induce cell-to-cell signaling
by interacting with high-affinity cell surface receptors.
Four receptor genes have been identified that encode
high-affinity receptors, and the number of receptor
species is extended by alternative splicing which changes
the ligand affinity of some receptors. Additionally, on the
cell surface, FGF2 interacts with heparan sulfate proteo-
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glycans (HSPGs) whose function may be the stabilization
of the FGF2-FGFreceptor (FGFR) complex [1]. 
An unusual feature of FGF2 is the use of alternative CUG
initiation codons to generate isoforms extended at the
amino terminus. For human FGF2, five isoforms have
been described; four high-molecular-weight (HMW)
forms where translation starts at four different CUGs, and
one low-molecular-weight (LMW) form where transla-
tion starts at the common translation start site [2–4].
Studies on the localization of FGF2 showed that the
HMW forms localized exclusively to the nucleus and nu-
cleolus [5–7]. The N-terminal region of the HMW forms
was shown to contain a nuclear localization signal and to
be able to lead fusion proteins to the nucleus [6, 8]. The
correct distribution of the HMW isoforms depends on the
methylation of three arginine residues present in the N
terminus [9–11].
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In contrast to the HMW forms, mechanisms controling
localization and the trafficking pathway of the 18-kDa
isoform are still a matter of debate. The 18-kDa isoform
does not contain any known secretory signal sequence,
and secretion from cells uses an alternative pathway
which is independent of the endoplasmic reticulum (ER)-
Golgi complex [12] and is energy dependent [13]. The se-
creted FGF2 proteins can act in an autocrine and
paracrine mode stimulating cell proliferation or migra-
tion [14]. FGF2 has been shown to accumulate in the nu-
cleus and to bind to nuclear chromatin when administered
exogenously [7, 15–19]. Moreover, the exogenous 18-
kDa isoform provided to endothelial cells enters the nu-
cleus specifically in the G1 phase of the cell cycle [15,
16]. This may include internalization of FGF2 and
translocation to the nucleus together with the receptor
[20–22]. Even intracrine FGF2 may enter the nucleus
complexed with truncated forms of FGFR-1 and FGFR-2
devoid of the transmembrane region [23]. 
The relative amounts of individual forms of FGF2 vary
among cell types and tissues during development and
adulthood [24–27]. In vivo studies, using transgenic
mice, showed that translation was regulated in a tissue-
specific manner [28]. A cytokine-specific induction of
HMW isoforms was observed in rat astrocytes [29] and a
direct correlation exists between HMW isoform expres-
sion and stress conditions such as heat shock and oxida-
tive stress in normal cells [27]. When expressed in
NIH3T3 cells, HMW forms but not the LMW form al-
lowed growth under low-serum conditions and in soft
agar [14]. The LMW form, forced to enter the nucleus by
fusion to the nuclear localization signal (NLS), was able
to mimic the effects of HMW forms inducing cells to
grow in low serum. These results point again to a specific
function of the protein depending on the localization
[11]. Neverthless, overexpression of either 18-kDa or
HMW FGF2 isoforms promotes cell transformation in a
dose-dependent manner [30] and upregulation of all
FGF2 isoforms was shown to be a critical component in
melanoma progression [31].
Genetic experiments addressing FGF2 function in mam-
mals have been performed in the mouse. Gene inactivation
of mouse FGF2 revealed a mild phenotype, including neu-
ronal defects, decreased bone mass, delayed wound heal-
ing and dilated cardiomyopathy [32–39]. In our experi-
ments, the gene-targeting experiment did not remove the
complete coding sequence of mouse FGF2, but only those
encoding amino acids C-terminal from amino acid 81, re-
sulting in an FGF2-lacZ fusion protein [38]. Nevertheless,
removal of this stretch of the protein was sufficient to
abolish FGF2 function [38, 39]. Since intracellular local-
ization has not been reported for mouse FGF2, we have
addressed this issue to potentially enable or improve stud-
ies in transgenic experiments. In addition, we set out to de-
fine areas of both long and short isoforms implicated in
nuclear or cytoplasmic localization, using N- and C-ter-
minal fusions of mouse FGF2 to green fluorescence pro-
tein (GFP). Our results reveal the existence of a potential
second nuclear localization sequence at the C terminus
which is only needed for the LMW 18-kDa isoform. 
Materials and methods
Analysis of genomic DNA
A 465-bp mouse Fgf2 cDNA probe (kindly provided by
J. Hébert [40]) was P32-labeled and hybridized to a mouse
genomic lambda library (derived from mouse strain
129SVJ). Double-positive phages were identified, iso-
lated, replated and rescreened. DNA from phages was
isolated, digested with Not1, and Southern blots were hy-
bridized to P32-labeled probes specific for exon 1, exon 2
or exon 3. Following further restriction enzyme diges-
tions, fragments were subcloned into pBluescript KS
(Stratagene Europe, Amsterdam, The Netherlands) and
analyzed. Sequence analyses was performed using Fgf2-
specific or pBluescript-specific primers. Sequence infor-
mation was deposited in GenBank (AY324448,
AY324449, AY324450, AY324451).
Constructs
GFP constructs. A DNA fragment coding for the 18-kDa
FGF2 [41] and a DNA fragment coding for the three
FGF2 isoforms were inserted in frame into the vectors
pEGFP-N or pEGFP-C (Clontech, Basel, Switzerland).
The cDNA fragment encoding the small FGF2 isoform
was extracted from the vector pmbFGF [41] with
SacI/AluI and inserted into SacI/SmaI sites of pEGFP-N3
to generate pATGGFP, or with NcoI (blunted with
Klenow)/PstI and inserted into XhoI (blunted)/SmaI sites
of pEGFP-C3 to generate pGFPATG. Vector pAT-
GKpGFP was constructed by isolating the insert with
SacI/KpnI from pmbFGF and subcloning it into pEGFP-
N2 digested with SacI/KpnI. Vectors pGFPATGKp or
pGFPATGB were obtained by digesting pGFPATG with
KpnI and BamHI, respectively, blunting the ends and re-
ligating the fragments. A KpnI/EcoRV fragment isolated
from pmbFGF was inserted into pEGFP-C2 digested
with KpnI/SmaI to generate pGFPKpTGA. Vector pGFP-
KpB was obtained by BamHI digestion of pGFPKpTGA
followed by religation. The vectors pGFPATG1 and pGF-
PATG21 were generated from pGFPATG by PCR ampli-
fication with mismatched oligonucleotides. In both vec-
tors, the 5¢ primer allowed amplification of part of the
pEGFP-C3 polylinker including the BglII site. In pGF-
PATG1, the 3¢ primer introduced a BamHI site and in
pGFPATG21 an ApaI site. This enabled the PCR product
to be introduced in pEGFP-C3 via these sites. Vectors
pGFPATG3 and pGFPATG4 were generated by introduc-
tion of a stop codon by PCR amplification, followed by
atmosphere. B16F10 cells were grown in MEM medium
(Gibco-BRL) supplemented with 10% FCS, 100 U/ml
penicillin and streptomycin and 0.1% glutamine. 293T
and NIH3T3 cells were transfected using calcium phos-
phate precipitation. All antibody stainings were per-
formed at room temperature (RT) in six-well plates. Cells
were grown on coverslips coated with poly-D-lysine 
(0.1 mg/ml) (Sigma) and fixed for 20 min in 4%
paraformaldehyde. After quenching with 50 mM NH4Cl2
in phosphate-buffered saline (PBS) for 5 min, the cells
were permeabilized with 0.1% Tween 20 (Fluka, Buchs,
Switzerland) for 5 min. Thereafter, the cells were incu-
bated at 37°C with RNase (200 mg/ml) for 30 min, DNA
was stained with propidium iodide (0.7 mg/ml) for 1 min
and cells were mounted with 2.5% 1,4-diazabicy-
clo(2,2,2)octane (DABCO) (Fluka), (w/v) in 10% PBS,
and 90% glycerol (98% solution). After permeabilization
with Tween 20, nonspecific binding sites were blocked
for 30 min with 10% goat serum in PBS. The cells were
then incubated for 30 min with the primary antibody, for
30 min with the secondary antibody, and mounted in
DABCO. Between each step, the cells were washed twice
with PBS. Confocal microscopy of cells was performed
on a Zeiss (Göttingen, Germany) Axiovert 100 micro-
scope (Zeiss Laser Scanning Microscope 410) with a 
¥ 63 Plan-Apochromat objective (1.4 oil). To detect pro-
pidium iodide, a helium laser was filtered at 543 nm. An
argon laser was used to detect GFP or fluoroscein 
fluorochrome. Images were processed with Photoshop
version 5.0 software (Adobe Systems Inc., San José,
Calif.).
Western blots
Transfected 293T cells were washed twice with ice-cold
PBS, placed on ice and scraped in cold extraction buffer
(20 mM Tris-HCl pH 7.5, 1% NP-40, 0.5% deoxy-
cholate, 0.5 mM EDTA). Cell suspensions were trans-
ferred into Eppendorf tubes. Cells were additionally lysed
by a cycle of freezing at –20 °C and thawing at RT, fol-
lowed by sonication. Protein content was evaluated by the
Bradford assay (Bio-Rad, Reinach, Switzerland). West-
ern blot analysis was performed according to standard
procedures. Total protein extracts were boiled for 5 min in
reducing SDS-PAGE sample buffer and electrophoresed
on 15% SDS-polyacrylamide gels. The proteins were
transferred to a nitrocellulose membrane which was
blocked for nonspecific binding in PBS containing 4%
lactate and 0.5% Tween 20 at RT for 1h. Membranes were
incubated with the primary antibody against FGF2 for 45
min, washed (4 ¥ 1 min) with PBS-4% lactate-0.5%
Tween 20, and incubated with the secondary antibody for
30 min. Finally, the membrane was washed (4 ¥ 15 min)
with PBS-0.5% Tween 20 and bands were visualized by a
chemiluminescent reaction (ECL; Amersham Life Sci-
ence, Otelfingen, Switzerland).
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ligation (BglII/EcoRI) into pEGFP-C3. The N-terminal
extension containing the two alternative translation start
sites which encode for the two HMW forms was extracted
from a genomic DNA fragment (construct p65RR4ex1)
derived from phage 65, containing exon 1 with 5¢ and 3¢
flanking regions. A DNA fragment containing the first 
40 bp of exon 1 and 300 bp of its 5¢ region was extract-
ed from p65RR4ex1 with NarI and subcloned into
pmbFGF2 digested with ClaI/NarI to generate vector
pCTGbFGF. The fragment encoding the three isoforms
was then isolated from pCTGbFGF with EcoRI/XhoI and
inserted into pEGFP-N1 or pEGFP-C3 digested with
EcoRI/XhoI to generate pCTGGFP or pGFPCTG. Vec-
tors pGFPCTGB, pGFPCTGKp and pGFPCTGSma were
generated by digesting pGFPCTG with BamHI, KpnI or
SmaI, respectively, and religating the vectors. pGFPCT-
GNa was constructed by isolating the fragment from
pGFPCTG with XhoI/NarI and inserting it into pEGFP-
C3 digested with XhoI/AccI. To generate pCTGKpGFP,
the fragment was isolated from pCTGGFP with KpnI and
inserted into pEGFP-N1 digested with KpnI. The cDNA
fragment encoding the four human FGF2 isoforms (vec-
tor pA [42]) was provided by Sophie Javerzat (Bordeaux,
France). An NcoI (blunt)/EcoRI fragment from this pA
vector was inserted into pEGFP-C1 digested with BglII
(blunt)/EcoRI to generate pGFPhATG. The XhoI/EcoRI
fragment from pA was inserted into pEGFP-C2 digested
with XhoI/EcoRI to generate pGFPhCTG. More specific
details on the cloning are available on request. Cloning
and PCR amplification of all constructs was corroborated
by sequence analysis to ascertain correct in-frame fusion
and absence of undesired mutations.
Flag constructs. For the generation of pATGflag, cDNA
encoding the 18-kDa isoform was retrieved from
pmbFGF with XhoI/EcoRI, made blunt and inserted into
blunted HindIII/SmaI sites of the vector pJl090 (provided
by Pascal Schneider, Institute of Biochemistry, Univer-
sity of Lausanne, Switzerland). pCTGflag was created by
inserting the fragment XhoI/EcoRI (blunted) from pCT-
GbFGF into the pJl090 vector digested with HindIII
(blunted)/SmaI.
CMVFGF2 constructs. pEGFP-N1 was digested with
BamHI/NotI, made blunt and religated to remove the GFP
coding region (vector pCMVN1). A SacI/EcoRI fragment
from pmbFGF was inserted into pCMVN1 digested with
SacI/EcoRI to generate pCMVATG. A BglII/BamHI frag-
ment from pCTGGFP was inserted into pCMVN1 di-
gested with BglII/BamHI to generate pCMVATG. 
Transfection and immunofluorescence
NIH3T3 and 293T cells were grown in DMEM medium
(Gibco-BRL, Basel, Switzerland) supplemented with 8%
fetal calf serum (FCS), 100 U/ml penicillin and strepto-
mycin, 1 mM Hepes (Gibco), and 1 mM mercaptoethanol
(Sigma, St. Louis, Mo.) in a humidified 5% CO2/95% air
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Mouse anti-Flag antibody M2 (kindly provided by Pascal
Schneider, Institute of Biochemistry, University of Lau-
sanne, Switzerland) was used at a dilution of 1/200. The
rabbit anti-bovine FGF2 antibody was obtained from
Sigma and used at 1/2000 dilution for immunoblotting
detection or at 1/200 dilution for immunofluorescence.
The secondary antibodies, goat anti-mouse conjugated to
fluorescein (DTAF; diluted 1/400), donkey anti-rabbit
conjugated to peroxidase (diluted 1/2000) or CY3 conju-
gated affinipure goat anti-rabbit IgG (diluted 1/400),
were obtained from Jackson ImmunoResearch Laborato-
ries Inc., West Grove, Pa.
Heparin-sepharose purification of FGF2-GFP fusion
protein
Transiently transfected 293T cells grown to subconflu-
ence were washed with PBS, scraped, centrifuged and re-
suspended in cold extraction buffer (20 mM Tris-HCl pH
7.5, 1% NP-40, 0.5% deoxycholate, 0.5 mM EDTA).
Cells were additionally lysed by a cycle of freezing at
–20°C and thawing at room temperature, followed by
sonication. The cell debris was pelleted by centrifugation
at 15,000 rpm for 15 min. The supernatant was applied to
a heparin-sepharose beads column (Pharmacia, Uppsala,
Sweden) in a 1-ml syringe. The column was washed with
cold extraction buffer and the heparin-binding proteins
were eluted with extraction buffer containing an increas-
ing concentration of NaCl (0.5, 1, 1.5, 2 and 3 M). GFP
fluorescence of eluted fractions was measured in 96-well
plates with a microplate fluorometer (Packard Instrument
Co., Meriden, Conn.).
Results
Mouse Fgf2 genomic structure and N-terminal 
extension
The Fgf2 gene locus was isolated and characterized 
using phages. These were subcloned and characterized by
restriction map and partial sequencing, and were com-
pared to the available sequence of the Fgf2 cDNA coding
for LMW FGF2. Sequencing of the intron-exon bound-
aries and high homology to the consensus splicing-site
sequences confirmed the predicted exon size and exon-
intron boundaries (not shown). The genomic organization
of the mouse Fgf2 gene is similar to that of the human
FGF2 gene. The three small exons (exon 1 175 bp, exon
2 104 bp, exon 3 186 bp) are separated by two large in-
trons. Because of the absence of overlapping phages the
precise size of intron 1 was not established but is esti-
mated to be at least 18 kb; intron 2 is 8 kb long. To ana-
lyze the possible N-terminal extension, the upstream se-
quence of the common translational start site (ATG) was
subcloned and analyzed. Alignment of 700 bp with the
corresponding region of rat Fgf2 [43] showed extensive
homology (not shown). Two potential alternative transla-
tion start sites correspond to the putative CTG start site of
the rat (fig. 1a). Analysis of the Fgf2 promoter sequence
confirmed the absence of TATA or CAAT box sequence
and a high content of GC. 
FGF2 HMW as well as LMW forms drive GFP to the
nucleus
To analyze the distribution of FGF2 isoforms and identify
domains involved in intracellular localization, we per-
formed transfection studies with a series of GFP-tagged
FGF2 fragments. For control experiments, GFP-coding
sequence was either eliminated or substituted with a flag
tag group. For expression of the 18-kDa isoform we used
the corresponding mouse cDNA. Correct expression of
the three isoforms and fusion proteins was confirmed by
Western blot (fig. 1b).
To analyze the subcellular localization of the different fu-
sion proteins, constructs were expressed in human em-
bryonic kidney 293T cells and mouse NIH3T3 fibrob-
lasts and examined by confocal microscopy (fig. 2). We
obtained the same results for both cell lines. The first
transfection experiments already revealed that GFP local-
ization was influenced by the fusion with FGF2. While
the GFP protein showed the expected unspecific localiza-
tion when expressed alone, expression of all the isoforms
was able to induce a nuclear localization of GFP. Fusion
with the small isoform (ATGGFP) localized GFP to the
nucleus, and a minor proportion to the cytoplasm. The
22-kDa isoform fused to GFP (GFPCTG) showed a
strong and exclusive nuclear/nucleolar localization.
When the three isoforms were coexpressed (CTGGFP),
the resulting localization was a merged pattern of the two
preceding constructs: light cytoplasmic and strong nu-
clear/nucleolar signals (fig. 2). The observed results were
specific to FGF2 and not due to aberrant effects induced
by the fusion with GFP protein. Immunostaining of FGF2
isoform expressed alone (CMVATG, CMVCTG) or fused
to a flag tag group (ATGflag, CTGflag) showed the same
cellular distribution. Localization was identical for the N-
or C-terminal position of GFP (GFPATG vs ATGGFP).
This localization was not mouse specific and was identi-
cal to GFP fused to human FGF2 (GFPhATG, GF-
PhCTG). Again, the HMW forms localized specifically
to the nucleus and the LMW form was found in the nu-
cleus with some staining in the cytoplasm. 
Signals in the amino terminus of HMW forms of
FGF2 lead to nuclear localization of a heterologous
protein
To determine whether the N-terminal sequence of the
mouse FGF2 mediates nuclear import, we generated a se-
ries of C-terminal deletion mutants (fig. 3). A first fusion
construct of a deletion was made with GFP in the C-ter-
minal position (CTGKpGFP), and resulted in nuclear and
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cytoplasmic staining (not shown). However, such con-
structs do not allow one to discriminate between CTG-
and ATG-initiated forms. Thus, FGF2 fragments were
fused in frame to GFP in the N-terminal position. Using
confocal microscopy, we observed a gradual increase in
the fluorescence in the cytoplasm when deleting the C
terminus. All proteins with C termini ranging from 155 to
81 (GFPCTG, fig. 2; GFPCTGB, GFPCTGKp, fig. 3) lo-
calized exclusively to the nucleus. GFPCTGNa was
found mostly in the nucleus but showed a very faint fluo-
rescence in the cytoplasm, indicating that nuclear accu-
mulation was less efficient. Within the nucleus, fluores-
cence seemed to colocalize with DNA (fig. 3). In con-
trast, GFPCTGSma localized homogeneously into all cell
compartments, indicating that further deletion of 23
amino acids from GFPCTGNa eliminated a specific se-
quence. This gradual loss in signal specificity may sig-
nify a loss of nuclear import/retention sequence or
change of protein conformation. 
Signals in the C-terminal region are essential for the
nuclear localization of the 18-kDa isoform and for
heparin binding
Despite the absence of the N-terminal NLS of the HMW
form, constructs ATGGFP and GFPATG still resulted in
nuclear localization (fig. 2), suggesting that other se-
quences in the FGF2 LMW form could be implicated in
nuclear import and/or retention. To determine the possi-
Figure 1. Mouse FGF2 contains two CTG translation initiation codons. (A) DNA sequence and deduced protein sequence of mouse FGF2,
illustrating the two CTGs and the ATG (+1) (grey background). Existing restriction enzyme sites and new sites used for generation of con-
structs are indicated. Underlined sequence points to the proposed NLS for the HMW forms [44]. (B) Western blot analysis demonstrates
the expression of the three isoforms (CMVATG, CMVCTG; 18 kDa, 21 kDa, 22 kDa). FGF2-flag (ATGflag, CTGflag) migrated at a
slightly higher molecular weight, whereas FGF2-GFP (ATGGFP, CTGGFP) migrated at ~42 kDa and 45 kDa, 46 kDa (one band). See fig-
ure 2 for scheme of the constructs. C; control, untransfected 293T cells. 
B
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ble importance of the carboxy terminus, we progressively
deleted the C-terminal region of the GFPATG fusion pro-
tein (fig. 4). Examination of the subcellular localization
showed two different patterns. In the shorter deletions,
GFPATG4 and GFPATG3, with either 4 or 8 C-terminal
amino acids missing, nuclear staining was abrogated and
fluorescence was mostly perinuclear (fig. 4). Deletion of
the last 19 or 32 amino acids (GFPATGB, GFPATG21;
fig. 4) resulted in a similar localization pattern, but with
a higher variability. In most of the cells (8 out of 10, con-
struct GFPATGB), staining was perinuclear (fig. 4), but a
few cells (2 out of 10) showed obviously unspecific stain-
ing (nuclear and cytoplasmic, not shown). This variabil-
ity, which was not seen in other constructs (beside GF-
PATGB and GFPATG21), might be due to the generation
of an unstable protein conformation or a partial accessi-
bility/inaccesibility of an interacting factor. One common
feature was the formation of very intense fluorescent
spots which localized in the cytoplasm and on the bound-
ary with the nucleus. When NIH3T3 cells were allowed to
grow for 48 h after transfection, the spots grew in size and
seemed to be harmful for the cells. The same phenome-
non was observed in 293T cells but occurred much faster,
due to higher transfection efficiency and/or more copies
entering the cell. Further deletion of another 17 amino
acids from the C terminus (GFPATG1) resulted in an un-
specific localization and disappearance of the fluorescent
spots (fig.4). This might suggest important sequences
Figure 2. Intracellular localization of expressed FGF2 fusion proteins. Both LMW and HMW isoforms (CMVCTG, CMVATG) show nu-
clear localization and this is reproduced in fusions to flag, and in N-terminal and C-terminal fusions to GFP. The LMW form shows an ad-
ditional weak fluorescence in the cytoplasm. Constructs are depicted with start sites indicated in bold (L, leucine; M, methionine); me-
thionine (AUG translation start site) is referred as +1. Overall patterns are summarized alongside each construct. N, nuclear, No, nucleo-
lar, C, cytoplasmic. Bar, 10 mm.
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within this stretch of 17 amino acids. On the other hand,
removal of these amino acids might render the protein
rather unstable, since several b-strands are missing ac-
cording to the three-dimensional structure of the protein
[1, 45]. Remarkably, lack of a further 25 amino acids
(GFPATGKp, ATGKpGFP) led to a consistent exclusion
of nucleolar fluorescence (fig. 4). This effect was only
seen with these 81 amino acids of FGF2, and thus whe-
ther a nucleolar localization or retention signal is miss-
ing, or whether a peculiar protein conformation is caus-
ing this effect is not clear. 
One of the characteristics of FGFs is their heparin-bind-
ing capacity. We thus addressed this property and tested
effects of different FGF2-GFP fusion constructs (fig. 5).
Cell extracts of transiently transfected 293T cells were
passed through heparin mini-columns and eluted with in-
creasing NaCl molarity. Fluorescence of the eluted frac-
tions was measured to monitor binding capacity of the fu-
sion proteins. Fractionation showed that the heparin-
binding affinity of the 18-kDa isoform was not altered by
the presence of GFP and that the fusion proteins eluted at
the expected NaCl molarity (1.5 M) (GFPATG; fig. 5). In
contrast, deletion of the C-terminal four amino acids im-
Figure 3. Influence of N-terminal sequences on subcellular local-
ization of HMW FGF2. The N terminus of the mouse FGF2 HMW
isoform is able to mediate nuclear localization in the absence of the
C terminus. The different plasmids were introduced in NIH3T3
cells and subcellular distribution was analyzed by confocal mi-
croscopy. In GFPCTGSma, DNA was counterstained with propid-
ium iodide (red staining). In GFPCTGNa, the insets depict GFP flu-
orescence (below) in comparison to a merge with propidium iodide
counterstaining (above). Bar, 10 mm. N, nuclear, No, nucleolar, C,
cytoplasmic.
Figure 4. Influence of C-terminal sequences on subcellular local-
ization of the 18-kDa FGF2 isoform. Constructs carrying C-ter-
minal deletions (GFPATG3, GFPATG4, GFPATGB, GFPATG21)
reveal loss of specific nuclear localization and appearance of 
perinuclear/cytoplasmic fluorescent spots. Further deletions re-
sulted in unspecific localization of fluorescence. Representa-
tive examples of localization are shown. Small insets depict red
counterstaining of DNA with propidium iodide. The image of 
GFPATG (fig. 2) is depicted for comparison. Bar, 10 mm. N, nu-
clear, No, nucleolar, C, cytoplasmic, S, juxtanuclear and reticular
staining.
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paired the heparin-binding capacity of FGF2 (GF
PATG4), and following further deletion (GFPATGB), he-
parin binding was barely detectable.
Since the last 74 amino acids of FGF2 seemed to contain
domains relevant for nuclear localization, we tested
whether this sequence is sufficient to direct localization
of a heterologous protein. C-terminal fragments were
subcloned to GFP (fig. 6). GFPKpTGA and GFPKpB
distributed broadly into the cell and formed small fluo-
rescent spots, similarly to GFPATGB (fig. 4), but of
smaller size. In addition, GFPKpTGA was not able to re-
tain any heparin binding (not shown). Further removal of
13 amino acids (GFPKp2) from the C terminus of GFP-
KpB or subcloning of the last 18 amino acids (GF-
PBTGA) resulted in localization indistinguishable from
GFP alone (fig. 2), suggesting that the C terminus alone
is not sufficient for nuclear localization.
Discussion
The biological function of at least 15 members of the FGF
family has now been addressed by homologous recombi-
nation in the mouse, with phenotypes ranging from early
embryonic lethality to subtle phenotypes [1]. Such gene-
targeting experiments not only allow one to address roles
of these growth factors in physiology and development,
but also in cancer research and with respect to human dis-
ease models. Moreover, they might enable the introduc-
tion of specific mutations allowing modification of the
intracellular localization of the proteins. In such an ex-
periment, we recently replaced the C-terminal part of
FGF2 by an in-frame fusion to a lacZ coding sequence
(Fgf2tm1Bee [38]), identical to CTGKpGFP or ATGKpGFP
(fig. 4). Deletion of the C-terminal half of FGF2 in vivo
was sufficient to abolish FGF2 function [38, 39]. Expres-
sion from this FGF2-lacZ fusion gene was only seen in
cartilage, and at a cellular level, the lacZ staining was
found in both the nucleus and cytoplasm of the positive
cells. These data illustrated that a fusion gene with FGF2
in the N-terminal position is expressed in mice, but is bi-
ologically not functional in the absence of the last 74
amino acids. 
Figure 5. The FGF2 C-terminus is required for heparin binding. Heparin-bound cell extracts of ATGGFP-, GFPATG- and CTGGFP-trans-
fected cells eluted at 1.5 M NaCl, whereas C-terminal deletions severely affected this heparin-binding capacity. Constructs are depicted in
figures 2 and 4. 
Figure 6. Intracellular localization by C-terminal sequences alone.
Fusions of GFP to fragments of the C terminus or to the C-terminal
half of FGF2 do not result in nuclear localization. The different plas-
mids were transfected into NIH3T3 cells and subcellular distribution
of fusion proteins was analyzed by confocal microscopy. Represen-
tative examples of localization are shown. Small insets depict red
counterstaining of DNA with propidium iodide. Bar, 10 mm. N, nu-
clear, C, cytoplasmic, S, juxtanuclear and reticular staining.
isoforms, and the nucleolar localization sequence was
postulated as being distinct from NLSs [33]. On the other
hand, elegant experiments on FGF3 have demonstrated a
nucleolar binding of FGF3 to the protein NoBP, mediated
by the C terminus and the same sequences as required for
the nuclear localization [48]. From our experiments, a nu-
cleolar signal is conceivably located in region +1 to +17.
Nevertheless, this nucleolar signal does not seem to be
sufficient to mediate nucleolar localization in the absence
of a nuclear localization sequence (GFPATGKp, AT
GKpGFP; fig. 4). Feasibly, the nucleolar localization of
the LMW isoform is equally linked to its NLS, as re-
ported for FGF3 [48].
By progressive deletion of the LMW form, we could
show that the C-terminal region is essential for correct
nuclear localization and heparin binding. Deletion of the
last 4 (GFPATG4), 8 (GFPATG3), 19 (GFPATGB) or 32
amino acids (GFPATG21) abrogated the specific nuclear
localization and induced juxtanuclear or reticular local-
ization of GFP fusion proteins. Removal of a further 17
(GFPATG1) or 42 amino acids (GFPATGKp) resulted in
a very homogenous and unspecific distribution. Never-
theless, the C terminus was not sufficient for nuclear lo-
calization and heparin binding (GFPKpTGA). From this
experiment, we suggest that the C terminus contains an
essential element that is not functional without the inter-
action with other parts of the protein. In concordance
with our data, point mutations of arginines at position
+115 and +117 (R149G, R151G) within a conserved C-
terminal sequence of FGF2 (R149G, R151G; fig. 7) led
to cytoplasmic localization in fusions to red fluorescent
protein in Schwann cells [46]. Equally, deletion of the last
6 or 9 amino acids at the C terminus of FGF1 impaired re-
ceptor and heparin binding [49]. 
The findings raise the question of the mechanism(s) re-
sponsible for nuclear accumulation of the 18-kDa isoform
observed both in transient and in stable transfectants. The
subcellular fate of FGF3 is controlled by competition of a
bipartite NLS with a secretory signal located near the
amino terminus [48, 50]. A functional NLS in the carboxyl
terminus was confirmed by fusing it to b-galactosidase and
targeting the chimeric protein to the nucleus [51]. FGF1
also accumulates in the nuclei, and deletion of an NLS
abolishes nuclear translocation [52, 53]. Localization of
FGF2 may be regulated following a similar mechanism,
even though classical NLSs seem to be missing. Neverthe-
less, the few amino acid motifs (for example YNTY; fig. 7)
which are homologous between different FGFs might be
implicated. This is supported by the effect of point muta-
tions in the neighboring amino acids (see above [46]). In-
sertion of point mutations in residues +27 to +31 of the hu-
man FGF2, which is in good agreement with a consensus
sequence for nuclear translocation [54], did not impair the
nuclear localization of the 18-kDa isoform [55]. Mutants
retained their receptor binding and mitogenic capacity but
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We now linked these transgenic experiments to experi-
ments in cell culture and addressed the intracellular lo-
calization of FGF2 in fusion to GFP. Initial experiments
were concordant with published results from human
FGF2 (and of other vertebrates) and demonstrate that the
HMW forms of mouse FGF2 are able to drive GFP to the
nucleus. However, these experiments also showed that
this characteristic was not restricted to the HMW forms,
since LMW-GFP fusion protein equally localized to the
nucleus with only a minor proportion in the cytoplasm.
This localization was also found for GFP fusion proteins,
using the human FGF2 protein. To confirm these results,
cells were transfected with vectors expressing FGF2 pro-
teins alone or fused to a flag tag group. Immunofluores-
cence detection confirmed the localization of GFP fusion
proteins suggesting that GFP did not cause aberrant ef-
fects. This is also supported by recent data, where both N-
and C-terminal fusion of GFP to rat FGF2 (the 18-kDa
form) did not affect correct export of the protein [41]. We
thus suggest that the small isoform of FGF2 (LMW, 18
kDa) is essentially located in the nucleus. 
To elucidate the localization of FGF2 in more detail, we
generated a series of C-terminal deletions of the HMW
form. We showed that amino acids between position –6
and +17 (GFPCTGSma, GFPCTGNa) play an essential
role in the nuclear localization of the HMW isoforms.
The entire N-terminal extension of the HMW has been
shown to target b-galactosidase to the nucleus but not to
the nucleolus [8]. Sequence comparison of the FGF2 pro-
tein sequence from different vertebrate species showed
that several glycine-arginine repeats of varying length are
present in the amino-terminal part. One of these motifs
(fig. 1) was shown to increase the nuclear accumulation
about threefold if inserted in the amino-terminal part of
the small isoform [44]. The N-terminal sequence is now
well recognized as a NLS, and recent data have shown
that posttranslational modifications which include
methylation of the arginines are essential for nuclear lo-
calization. In the absence of methylation, HMW FGF2 is
equally distributed between cytoplasm and nucleus [11].
A first step into the understanding of differential func-
tions (or localization) might be the identification of pro-
teins specifically binding to the HMW isoform, as for ex-
ample the exclusive coimmunoprecipitation and colocal-
ization with survival of motoneuron protein (SMP) in rat
Schwann cells [46]. The HMW form, but not the LMW
form has also been reported to specifically associate with
chromatin and histone H1 [47]. 
The nuclear accumulation of the small isoform suggests
a synergistic interaction of several signals. Apparently,
two separate signals, the amino-terminal extension and a
putative nucleolar localization sequence within the LMW
sequence, are needed for nuclear and nucleolar localiza-
tion of the HMW FGF2 forms. Nucleolar localization of
FGF2 has been reported both for the long and the short
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had a 100-fold reduced urokinase-type plasminogen acti-
vator capacity. Interestingly, this latter activity was restored
by addition of soluble heparin [55]. Similar results on the
biological activity of FGF2 were obtained with another
mutant in which residues in different regions of FGF2 were
mutated, suggesting that alteration of the tertiary structure
rather than of the primary structure of the protein is re-
sponsible for these modifications [56]. 
Neither N-terminal region (ATGKpGFP; fig. 4), C-termi-
nal region (GFPKpTGA; fig. 6) nor fusions of the entire
18-kDa isoform with the other reporter genes (chloram-
phenicol acetyltransferase [6]; pyruvate kinase [44]) were
able to locate to the nucleus, thus indicating that the LMW
isoform does not contain a simple NLS and correct local-
ization thus depends on a tight interaction between N and
C termini. Nuclear localization of the 18-kDa isoform
might thus be dependent on the intact three-dimensional
structure and less or not at all on the presence of a specific
NLS. Many small proteins enter the nucleus by diffusion
rather than by NLS and energy-dependent mechanisms.
The 18-kDa isoform might thus diffuse into the nucleus
through the nuclear pore and bind to chromatin, staying in
the nuclear compartment during the interphase [55]. The
protein structure of FGF2 has been known for nearly a
decade and is composed of a b trefoil structure with four-
stranded b-sheets in a triangular array [1, 45, 57]. The N-
terminal and the C-terminal part of the protein are juxta-
posed and are both part of the same b-sheet. Thus, certain
modifications in the C terminus might directly affect the
structure of this b-sheet. In contrast, the N-terminal exten-
sion of the HMW forms seems not to participate in the
structure, and is probably accessible as an NLS indepen-
dent of most changes in the protein core. Heparin-binding
regions are located around b-strands 10 and 11, and do not
overlap with the sites binding to the receptor [1, 58]. 
The 18-kDa isoform might be first secreted to the cell
surface before being transported to the nucleus. Local-
ization might depend on association with other proteins,
which is tightly dependent on the three-dimensional
structure. FGFR and heparan sulfate proteins were shown
to translocate to the nucleus and might be implicated in
this alternative signaling pathway. They might be actively
implicated in nuclear transport acting as carrier proteins
[22, 49]; alternatively, their functions might be to stabi-
lize and protect FGF2 proteins without affecting free dif-
fusion [59]. Recently, a protein implicated in trafficking
internalized FGF2, translokin, has been demonstrated to
bind between b strands 2 and 5 and between b strands 8
and 10 [60]. The latter includes amino acids 103–126,
which might explain the lack of any specific localization,
when comparing GFPATG21 and GFPATG1 (fig. 4). If
binding of FGF2 to HSPGs is required for nuclear local-
ization, as demonstrated recently [49], any effect on one
of the heparin-binding sites (b strands 1 and 2, b strands
10 and 11 [1]) will affect nuclear localization. Since even
the smallest C-terminal deletions (GFPATG4) affected
heparin binding (fig. 6), this might explain the loss of nu-
clear localization (fig. 4) as well. 
In summary, we have characterized the mouse FGF2 and
its intracellular localization. While the N terminus is es-
sential for nuclear localization of the HMW isoforms, the
C terminus is only important for nuclear localization of
the LMW isoform, possibly by interacting with N-termi-
nal sequences of the protein. 
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Figure 7. Protein sequence of the C terminus of the FGF family. Alignment of the C-terminal amino acids of mouse and human FGF2,
FGF1, FGF3 and FGF9 (mouse only) reveals only very few highly conserved amino acids. Note that constructs pGFPATG4 and pGFPATG3
lack only the last 4 or 8 amino acids, respectively, including the conserved FLP sequence (pGFPATG3). Numbering refers to the protein
sequence of mouse FGF2 (ATG = +1). Asterisk indicates stop codon: The C-terminal sequence of FGF3 is not indicated completely.
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